Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • About Us
    • Our Coverage
    • Team
Analyst Comment

Qlife Holdings interview with CFO Kasper Rousøe – highlights from Q3 report!

By Claus ThestrupCEO, Sweden
Qlife Holding

Watch Qlife’s CFO walk you through latest PnL, Balance sheet and cashflow development. Focus lies on the latest rights issue and net proceeds, cost cutting program and financial status. Then we dive into the pipeline and announcement regarding FIND project. You also get a market update on when Qlife expect to launch their CRP product and latest improvements to Egoo device.

See the video here: https://lnkd.in/dvDQXgtx 
 
Qlife Holding AB is a med-tech group that strives to revolutionize the market for clinical biomarker and virus tests. By enabling tests at home as a complement to tests in healthcare, access to important health information is facilitated, which can contribute to better treatment and potentially prevent diseases.
Qlife Holding was formed in October 2019 and received the certification ISO 13485:2016 the same year, which means that Qlife meets all requirements for the manufacture and sale of in-vitro diagnostic analyzers and reagents. The first capsules in the company's product, Egoo.Health Platform, were CE marked for professional use in early 2020. The company has patent protection for key parts of its technology.
Qlife Holding AB is listed on Nasdaq First North Stockholm with ticker QLIFE.

Due to technical issues with the original interview – this video contains pre-recorded highlights from the Q3 report.

Disclaimer: HC Andersen Capital receives payment from Qlife Holding for a Corporate Visibility/Digital IR subscription agreement. /Claus Thestrup 13.20. 06-December-2022.

Qlife Holding AB is a med-tech group that strives to revolutionize the market for clinical biomarkers and virus tests. By enabling tests at home as a complement to tests in healthcare, access to important health information is facilitated, which can contribute to better treatment and potentially prevent diseases. The first capsules in the company's product, Egoo.Health Platform, were CE-marked for professional use in early 2020. The company has patent protection for key parts of its technology. The Danish-based company is listed on Nasdaq First North Stockholm.

Read more on company page
Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.